User profiles for Rudolf Maria Huber

Rudolf Huber

University of Munich
Verified email at med.uni-muenchen.de
Cited by 22056

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry

…, S Gläser, FJF Herth, T Welte, RM Huber… - European …, 2015 - Eur Respiratory Soc
After introduction of the new international guidelines on idiopathic pulmonary fibrosis (IPF)
in 2011, we investigated clinical management practices for patients with IPF according to …

[HTML][HTML] Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)–pretreated non–small-cell …

…, J Stöhlmacher-Williams, A Märten, RM Huber… - Journal of Thoracic …, 2015 - Elsevier
Introduction Afatinib is an effective first-line treatment in patients with epidermal growth factor
receptor (EGFR)-mutated non–small-cell lung cancer (NSCLC) and has shown activity in …

The European Respiratory Society and European Society of Thoracic Surgeons clinical guidelines for evaluating fitness for radical treatment (surgery and …

…, MK Ferguson, C Faivre-Finn, RM Huber… - European journal of …, 2009 - academic.oup.com
The European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS)
established a joint task force with the purpose to develop clinical evidence-based …

[HTML][HTML] Heat shock protein 70 (Hsp70) peptide activated natural killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after …

…, H Hautmann, M Hautmann, RM Huber… - Frontiers in …, 2015 - frontiersin.org
Heat shock protein 70 (Hsp70) is frequently overexpressed in tumor cells. An unusual cell
surface localization could be demonstrated on a large variety of solid tumors including lung, …

Fiberoptic bronchoscopic balloon dilatation in malignant tracheobronchial disease: indications and results

H Hautmann, F Gamarra, KJ Pfeifer, RM Huber - Chest, 2001 - Elsevier
Study objectives Bronchoscopic balloon dilatation(BBD) has become a valuable tool in the
treatment of benigntracheobronchial stenoses. The objective of this study was to …

[HTML][HTML] Interleukin-22 is frequently expressed in small-and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells

…, S Rothenfußer, M Schnurr, RM Huber… - Journal of Thoracic …, 2013 - Elsevier
Introduction: In lung cancer, interleukin-22 (IL-22) expression within primary tissue has been
demonstrated, but the frequency and the functional consequence of IL-22 signaling have …

SCLC–state of the art and what does the future have in store?

K Kahnert, D Kauffmann-Guerrero, RM Huber - Clinical lung cancer, 2016 - Elsevier
Worldwide, the total number of diagnosed lung cancer cases amounts to 1.8 million every
year. Small-cell lung cancer (SCLC) accounts for about 15% to 17% of all diagnosed lung …

Palliative endobronchial brachytherapy for central lung tumors: a prospective, randomized comparison of two fractionation schedules

RM Huber, R Fischer, H Haŭtmann, R Pöllinger… - Chest, 1995 - Elsevier
Aim of the study Remote high dose rate brachytherapy is an effective local treatment modality
for central lung tumors and has the potential to improve survival time. Optimal dose and …

Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification

…, P Van Schil, GV Scagliotti, RM Huber… - European …, 2011 - Eur Respiratory Soc
Respiratory Society (ERS), as well as the International Association for the Study of Lung
Cancer (IASLC) and the American Thoracic Society (ATS)[1]. This classification is now …

Effects of the Hedgehog pathway inhibitor GDC-0449 on lung cancer cell lines are mediated by side populations

…, J Mysliwietz, J Ellwart, F Gamarra, RM Huber… - Clinical and …, 2012 - Springer
The hedgehog (Hh) signaling pathway has been shown to be activated in the cancer stem
cells of several tumor entities. The Hh inhibitor GDC-0449 has been proven to be effective in …